Physician profile
Nadeem Qurashi
NPI 1033290168
$15,896.65
in general payments reported to CMS, 2019-2025
55 companies · $4,446 in 2025
The $4,446 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,818 · 2020: $810 · 2021: $1,184 · 2022: $1,485 · 2023: $695 · 2024: $2,459 · 2025: $4,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,450 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Consulting Fee: $1,638 · Travel and Lodging: $1,376 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Consulting Fee | $1,637.50 |
| Travel and Lodging | $1,376.44 |
| Education | $135.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,577.16 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $2,239.37 | 2019-2025 | Calquence, Enhertu, Tagrisso |
| Seagen INC. | $1,868.02 | 2019-2022 | |
| Exelixis INC. | $1,781.00 | 2019 | |
| Amgen INC. | $847.46 | 2019-2023 | Lumakras |
| E.R. Squibb & Sons, L.L.C. | $754.13 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $496.54 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $346.18 | 2019-2024 | Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $327.09 | 2021-2025 | Enhertu |
| Pfizer INC. | $307.54 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $260.90 | 2019-2022 | |
| Eisai INC. | $260.09 | 2019-2024 | |
| Genzyme Corporation | $238.15 | 2019-2025 | |
| Genentech USA, INC. | $185.61 | 2021-2023 | Tecentriq, Polivy, Columvi |
| Astellas Pharma US INC | $167.57 | 2019-2025 | Xospata, Vyloy |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Qurashi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.